Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Renal Impairment · Urinary Tract Infection · SPRO

Spero Therapeutics

Spero Therapeutics clinical programs — 21 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
675 Massachusetts Ave, 14th Floor, Cambridge, MA 02139, US HQ
2013 Founded
45 Employees
Public company Type
SPRO · NYSE Ticker
Company details
Status
Public
HQ
675 Massachusetts Ave, 14th Floor, Cambridge, MA 02139, US
Founded
2013
Employees
45
Programs
21
Drugs
9
Patents
16
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Spero Therapeutics projects

21 ClinicalTrials.gov programs sponsored by Spero Therapeutics.

Spero Therapeutics has 21 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

21 programs

Clinical programs

  1. SPR994-305

    Spero Therapeutics

    complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)

    phase 3 small molecule active

    1 trial

  2. TBP-PI-HBr

    Spero Therapeutics

    Urinary Tract Infection

    phase 3 small molecule completed

    1 trial

  3. TBPM-PI-HBr

    Spero Therapeutics

    Complicated Urinary Tract Infection

    phase 3 small molecule completed

    1 trial

  4. Placebo

    Spero Therapeutics

    Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

    phase 2 small molecule completed

    1 trial

  5. SPR720

    Spero Therapeutics

    Mycobacterium Avium Complex

    phase 2 small molecule terminated

    1 trial

  6. SPR206

    Spero Therapeutics

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  7. SPR206

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  8. SPR720

    Spero Therapeutics

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  9. SPR720

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  10. SPR720 for SAD

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  11. SPR741

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  12. SPR994

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  13. TBP-PI-HBr

    Spero Therapeutics

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  14. TBP-PI-HBr

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  15. TBPM-PI-HBr

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    3 trials

  16. Tebipenem Pivoxil Hydrobromide

    Spero Therapeutics

    Diabetes

    phase 1 small molecule completed

    1 trial

  17. Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo

    Spero Therapeutics

    TQT Study

    phase 1 small molecule completed

    1 trial

  18. Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  19. Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)

    Spero Therapeutics

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  20. Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference

    Spero Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  21. Tebipenem tablet form

    Spero Therapeutics

    Relative Bioavailability

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Spero Therapeutics have?

21 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.